Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 27 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Alzheimer's disease is a multifactorial neurodegenerative disorder characterized by amyloid- β aggregation, oxidative stress, neuroinflammation, tau hyperphosphorylation, and cholinergic dysfunction. The limited efficacy of current therapies has driven the development of multitargetdirected ligands (MTDLs). Chalcones represent a versatile scaffold for modulating multiple ADrelated targets. This review provides a concise analysis of the structure-activity relationship (SAR) of chalcone derivatives, highlighting the effects of hydroxylation, methoxylation, halogenation, and heterocyclic hybridization on biological activity. Electron-withdrawing substituents (e.g., halogens, -CF₃) enhance enzyme inhibition and MAO-B selectivity, whereas electron-donating groups (e.g., hydroxyl and methoxy groups) contribute to antioxidant activity, metal chelation, and hydrogen bonding interactions. Scaffold hybridization and optimized linker design further improve multitarget engagement, including AChE/BuChE inhibition, MAO-B modulation, and anti-amyloid activity. However, despite promising in vitro and in silico findings, translational limitations remain due to insufficient in vivo validation and pharmacokinetic constraints. Overall, chalcone-based MTDLs provide a rational framework for the development of next-generation anti-Alzheimer agents.

What this study adds

Evidence grade: Low

This review of chalcone derivatives describes how chemical modifications affect activity against Alzheimer-related targets such as AChE, BuChE, MAO-B, and amyloid. It states that translation is limited by insufficient in vivo validation and pharmacokinetic constraints, so no treatment or cure is established.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Paliwal, D., & Thakur, A. (2026). Exploring the Therapeutic Potential of Chalcones in Alzheimer’s Disease: Mechanistic Insights and SAR Perspectives. Mini-Reviews in Medicinal Chemistry. https://doi.org/10.2174/0113895575457432260717112508

Vancouver

Paliwal D, Thakur A. Exploring the Therapeutic Potential of Chalcones in Alzheimer’s Disease: Mechanistic Insights and SAR Perspectives. Mini-Reviews in Medicinal Chemistry. 2026. doi:10.2174/0113895575457432260717112508. PMID: 42522305.

BibTeX

@article{paliwal2026-42522305,
  author  = {Paliwal, Deepika and Thakur, Aman},
  title   = {{Exploring the Therapeutic Potential of Chalcones in Alzheimer’s Disease: Mechanistic Insights and SAR Perspectives}},
  journal = {Mini-Reviews in Medicinal Chemistry},
  year    = {2026},
  doi     = {10.2174/0113895575457432260717112508},
  pmid    = {42522305},
  url     = {https://doi.org/10.2174/0113895575457432260717112508}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review of chalcone derivatives describes how chemical modifications affect activity against Alzheimer-related targets such as AChE, BuChE, MAO-B, and amyloid. It states that translation is limited by insufficient in vivo validation and pharmacokinetic constraints, so no treatment or cure is established.

Study details

How this study scored 27/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 27 of 100.27 of 100 points earned73 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Mini-Reviews in Medicinal Chemistry)
Journal's citation record 1 / 4 Mini-Reviews in Medicinal Chemistry: journal h-index 126 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Aman Thakur: h-index 9 (OpenAlex, whole career)
Institution's track record 0 / 3 Galgotias University: institution h-index 129 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 42522305)
Free to read 0 / 2 Behind a paywall — scores zero
Total 27 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →